6-KThe Wire
Enlivex Ltd. files 6-K
Filed Mar 23, 2026 · 3mo ago · Accession 0001213900-26-032634
Plain English
Enlivex Ltd. announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug application for Allocetra™ for the treatment of patients with moderate-to-severe age-related symptomatic primary knee osteoarthritis. This clearance allows Enlivex to begin a global Phase 2b clinical trial.
Filing details
- Company
- Enlivex Ltd.
- Ticker
- ENLV
- CIK
- 1596812
- Form type
- 6-K
- Filing date
- Mar 23, 2026
- Report date
- Mar 23, 2026
- Document
- ea0282900-6k_enlivex.htm
- Size
- 24 KB